Inborn errors of metabolism (IEM) represents a group of ~500 monogenic disorders each associated with inherited defect in a metabolic enzyme, regulatory protein, or complex. Despite the wellestablished genetic linkage and clinical manifestations for IEMs, there remains a lack of transformative therapy for many of them. This is in large part due to the conceptual challenge that the majority of IEMs result in the loss of enzyme function, rendering pharmacologic rescue difficult. Our team at the Structural Genomics Consortium (SGC), University of Oxford aims to address this gap using structural biology approaches to enable drug discovery for IEMs.
